In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

British Journal of Cancer

Volumn 89, Issue 12, 2003, Pages 2305-2311

  Simoens, C ^a   Korst, A E C ^a   De Pooler, C M J ^b   Lambrechts, H A J ^a   Pattyn, G G O ^a   Faircloth, G T ^c   Lardon, F ^a   Vermorken, J B ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

^c PharmaMar USA Inc   (United States)

Author keywords

Cell cycle; ET 743; Radiation; Radiosensitisation

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; CELL PROTEIN; ISOQUINOLINE DERIVATIVE; RADIOSENSITIZING AGENT; SULFORHODAMINE B; TRABECTEDIN;

ARTICLE; BLADDER TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL KILLING; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LUNG TUMOR; MITOSIS INHIBITION; MULTIMODALITY CANCER THERAPY; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION EXPOSURE; RADIOSENSITIVITY; RADIOSENSITIZATION; TONGUE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DIOXOLES; HUMANS; ISOQUINOLINES; LUNG NEOPLASMS; RADIATION-SENSITIZING AGENTS; TETRAHYDROISOQUINOLINES; TONGUE NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 0842287213     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601431     Document Type: Article

References (34)

1. Chou TC, Talalay P (1984) Quantitative analysis of dose - effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
2. Damia G, Silvestri S, Carrassa L, Filliberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiences in DNA-repair pathways. Int J Cancer 92: 583-588
3. Demetri GD (2002) ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 13(Suppl 1): S7-S9
4. D'Incalci M, Erba E, Damia G, Galliera E, Carrassa L, Marchini S, Mantovani R, Tognon G, Fruscio R, Jimeno J, Faircloth GT (2002) Unique features of the mode of action of ET-743. Oncologist 7: 210-216
5. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37: 97-105
6. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW (2002) Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 62: 3377-3381
7. Garcia Nieto R, Manzanares I, Cuevas C, Gago F (2000) Increased DNA binding specificity for antitumor ecteinascidin 743 through protein - DNA interactions. J Med Chem 43: 4367-4369
8. Geh JI (2002) The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 38: 300-313
9. Ghielmini M, Colli E, Erba E, Bergamaschi D, Pampallona S, Jimeno J, Faircloth G, Sessa C (1998) In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). Ann Oncol 9: 989-993
10. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT, European Osteosarcoma Intergroup (EOI) (1999) High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 10: 1233-1240
11. Hennequin C, Favaudon V (2002) Biological basis for chemo-radiotherapy interactions. Eur J Cancer 38: 223-230
12. Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, Clark G, Von Hoff DD (1998) In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9: 981-987
13. Jimeno JM, Faircloth G, Cameron L, Meely K, Vega E, Gomez A, Fernandez Sousa-Faro JM, Rinehart K (1996) Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743. Drugs Future 21: 1155-1165
14. Kim TY, Yang SH, Lee SH, Park YS, Im YH, Kang WK, Ha SH, Park CI, Heo DS, Bang YJ, Kim NK (2002) A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol Cancer Clin Trials 25: 238-243
15. Le Cesne A, Misset JL, Demetri G, Lopez-Martin JA, Blay JY, van Oosterom A, Judson I, Brain E, Yovine A, Maki R, Gomez J, Guzman C (2001) Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule. Eur J Cancer 37(Suppl 6): 34
16. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA (1996) Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 56: 5198-5204
17. Li WW, Takahashi N, Jhanwar S, Cordon Cardo C, Elisseyeff Y, Jimeno J, Faircloth G, Bertino JR (2001) Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 7: 2908-2911
18. Lukka H, Hirte H, Fyles A, Thomas G, Elit L, Johnston M, Fung Kee Fung M, Browman G (2002) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer - a meta-analysis. Clin Oncol 14: 203-212
19. Moore BM, Seaman FC, Wheelhouse RT, Hurley LH (1998) Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2. J Am Chem Soc 120: 2490-2491
20. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH (1997) Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 208: 151-158
21. Parma G, Bauer J, Noberasco C, Perotti A, Izquierdo M, Jimeno J, Marsoni S, Colombo N, Capri G, Sessa C (2003) Yondelis™ (ET-743, trabectedin) antitumor activity in ovarian cancer patients pretreated with platinum-taxane regimens (50PD). Ann Oncol 14(Suppl 3): iii52
22. Pauwels B, Korst AEC, De Pooter CMJ, Pattyn GGO, Lambrechts HAJ, Baay MFD, Lardon F, Vermorken JB (2003) Comparison of the sulforhodamine B test and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol 51: 221-226
23. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355: 949-955
24. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ectainiascidin 743, a potent antitumor compound from the caribbean tunicate ecteinascidia turbinata. Biochemistry 35: 13303-13309
25. Rose PG (2002) Chemoradiotherapy for cervical cancer. Eur J Cancer 38: 270-278
26. Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29: 450-474
27. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
28. Taamma A, Misset J L, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, Rosing H, Jimeno J M, Cvitkovic E (2001) Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19: 1256-1265
29. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama S, Popescu N, Kraemer KH, Pommier Y (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7: 961-966
30. Terasima R, Tolmach LJ (1963) X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140: 490-492
31. Vindelov LL, Christensen IJ, Nissen NI (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327
32. Zelek L, Yovine A, Brain E (2000) Preliminary results of phase II study of ecteinascidin-743 (ET-743) with the 24h (H) continuous infusion (CI) Q3weeks schedule in pretreated advanced/metastatic breast cancer (A/MBC) patients (Pts). Proceedings of the 11th NCI EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, p. 85a.
33. Zewail Foote M, Hurley LH (1999) Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 42: 2493-2497
34. Zewail Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH (2001) The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 8: 1033-1049